Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: Results of the HOVON 76 Trial

Blood

Volumn 118, Issue 9, 2011, Pages 2413-2419

  Kneppers, Evelien ^a   Van Der Holt, Bronno ^b   Kersten, Marie Jose ^c   Zweegman, Sonja ^d   Meijer, Ellen ^b   Huls, Gerwin ^e   Cornelissen, Jan J ^b   Janssen, Jeroen J ^d   Huisman, Cynthia ^c   Cornelisse, Petra B ^b   Bruijnen, Cheryl P ^a   Emmelot, Maarten ^a   Sonneveld, Pieter ^b   Lokhorst, Henk M ^a   Mutis, Tuna ^a   Minnema, Monique C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; HLA DR ANTIGEN; LENALIDOMIDE; THALIDOMIDE; THYMOCYTE ANTIBODY; VINCRISTINE;

ABNORMAL LABORATORY RESULT; ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TOXICITY; BONE MARROW DISEASE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOMODULATION; INFECTION; MAINTENANCE THERAPY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONMYELOABLATIVE CONDITIONING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE;

EID: 80052398586     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-348292     Document Type: Article

References (15)

1. Lokhorst H., Einsele H., Vesole D., et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol. 2010;28(29):4521-4530.
2. Bruno B., Rotta M., Patriarca F., et al.Acomparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356(11):1110-1120. (Pubitemid 46425595)
3. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107(9):3474-3480.
4. Rosinol L., Perez-Simon J.A., Sureda A., et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112(9):3591-3593.
5. Van de Donk N.W., Kroger N., Hegenbart U., et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood. 2006;107(8):3415-3416.
6. Kroger N., Badbaran A., Lioznov M., et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol. 2009;37(7):791-798.
7. Minnema M.C., Van der Veer M., Aarts T., Emmelot M., Mutis T., Lokhorst H.M. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia. 2009;23(3):605-607.
8. Kneppers E., Lokhorst H.M., Eeltink C.M., et al. Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. Clin Lymphoma Myeloma Leuk. 2010;10(2):138-143.
9. Blade J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115-1123. (Pubitemid 28435189)
10. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473. (Pubitemid 44264086)
11. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956. (Pubitemid 41754712)
12. Sonneveld P., Schmidt-Wolf I., Van de Holt B., et al. HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116:Abstract 60.
13. Rotta M., Storer B.E., Sahebi F., et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood. 2009;113(14):3383-3391.
14. Hsu A.K., Quach H., Tai T., et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood. 2011;117(5):1605-1613.
15. Wolschke C., Schonland S., Hegenbart U., et al. Dose finding study of lenalidomide as maintenance therapy in multiple myeloma after allogeneic stem cell transplantation [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116:Abstract 6.